جست‌وجوی استاد و پژوهشگر

Kine Pedersenمشاهده پروفایل

دانشیار

• Health Economic Analysis
• Disease Simulation Modeling
• Cervical Cancer Prevention
• +۵ مورد دیگر

Kine Pedersen is an Associate Professor at the Department of Health Management and Health Economics within the Faculty of Medicine at the University of Oslo. Her academic career focuses on health economic analysis, disease simulation modeling, and evaluation of healthcare interventions with particular expertise in cervical cancer prevention, HPV-related disease control, and primary care services. She has established herself as a leading researcher in cost-effectiveness analysis of preventive healthcare strategies within the Norwegian healthcare system. Education: PhD in Health Economics and Health Policy, University of Oslo (2018) M.Phil. in Health Economics, Policy and Management, University of Oslo (2014) BA in Economics, University of Oslo (2012) BA in Health Management and Health Economics, University of Oslo (2011) Dr. Pedersen's research program centers on developing and applying sophisticated mathematical models to evaluate preventive healthcare interventions, with a strong emphasis on cervical cancer screening programs and HPV vaccination strategies. Her work bridges health economics, epidemiology, and clinical practice to inform evidence-based healthcare policy. She has made significant contributions to understanding how to optimize screening protocols for vaccinated versus unvaccinated populations and has extensively studied the cost-effectiveness of various approaches to accelerate cervical cancer elimination in Norway. Her recent publications (2022-2024) reveal an expanding research portfolio that now includes telemedicine applications for chronic disease management and team-based primary care models, while maintaining her core focus on cancer prevention. The consistent thread through her work is the application of rigorous health economic methodologies to evaluate preventive interventions, with particular attention to structural uncertainty in modeling and real-world implementation challenges. Scientific Awards: The Society for Medical Decision Making's Lee B. Lusted Student Prize in Health Services and Policy Research Dr. Pedersen teaches HEVAL5120: Modelling in Economic Evaluation I and HMET4210: Research Design. Her research is supported through collaborations with the Cancer Registry of Norway, Center for Health Decision Science at Harvard T.H. Chan School of Public Health, Norwegian Institute of Public Health, and Department of Biostatistics at Aarhus University. She leads or participates in several significant research projects including ASCERTAIN, Optimal Cervical Cancer Prevention Policies (CC-PREVENT), and EXCEED – Network for economic evaluation in Norway. Her work directly informs Norwegian healthcare policy and contributes to international efforts to eliminate cervical cancer through evidence-based preventive strategies.

Martijn Froelingمشاهده پروفایل

استادیار

• Quantitative MRI
• Diffusion Tensor Imaging
• Neuromuscular diseases
• +۷ مورد دیگر

Martijn Froeling serves as an Assistant Professor at University Medical Center Utrecht, actively contributing to the Precision Imaging research group within the High Field division. His work bridges advanced MRI technology development with clinical applications targeting critical health domains including brain cancer, circulatory health, dementia, and musculoskeletal disorders. His academic foundation includes: Master's in Biomedical Engineering from Eindhoven University of Technology (July 2009) PhD in Diffusion Tensor Imaging of the human forearm from Amsterdam University Medical Center and Eindhoven University of Technology (October 2012) Dr. Froeling's research centers on pioneering quantitative MRI methodologies, with specialized expertise in Diffusion Tensor Imaging (DTI) across multiple organ systems (brain, peripheral nerves, muscle, kidney, heart). He drives innovation in 7T MRI hardware development—including specialized coils for multi-nuclei imaging—and conducts clinical studies focused on neuromuscular diseases. His QMRITools software platform for Mathematica enables sophisticated quantitative MRI analysis, directly supporting his mission to 'see the unseen' for advancing clinical diagnostics in cancer, cardiovascular disease, stroke, and MSK conditions. Analysis of his 2024-2025 publications reveals a cohesive research trajectory: DTI applications dominate clinical studies (hamstring injuries, fasciculation mapping), while parallel technical work advances ultra-high-field hardware (double-tuned coils for ²H/³¹P imaging). This dual focus on clinical impact and technological innovation demonstrates his commitment to translating engineering breakthroughs into tangible medical solutions. No scientific awards were documented in the provided materials. While the text confirms Dr. Froeling's role in supervising PhD work (evidenced by his PhD completion under prominent supervisors), no current students or specific grant funding details are explicitly mentioned in the source material. He operates within the High Field group at University Medical Center Utrecht, leading the Precision Imaging research initiative. This team specializes in developing cutting-edge MRI hardware (particularly for 7T systems), maintaining the QMRITools analysis platform, and executing clinical trials targeting neuromuscular pathologies alongside broader applications in oncology and cardiovascular medicine.

• Breast cancer
• Molecular pathology
• Tumour microenvironment
• +۶ مورد دیگر

Professor Sandra O'Toole is a distinguished Professor of Pathology at the University of Sydney's Faculty of Medicine and Health, School of Medical Sciences. She also serves as a Senior Staff Specialist at Royal Prince Alfred Hospital and a Senior Pathologist at the Garvan Institute of Medical Research. With internationally recognized expertise in breast cancer and molecular pathology, Professor O'Toole contributes significantly to both clinical practice and academic research in oncology. Professor O'Toole holds an MBBS (Hons I), BMedSc (Hons I), PhD, and is a Fellow of the Royal College of Pathologists of Australasia (FRCPA) and Fellow of the Faculty of Science (RCPA) (FFSc). Her extensive academic credentials reflect her deep expertise in pathology and medical sciences. Professor O'Toole's research spans multiple critical areas in cancer pathology, with a primary focus on breast cancer. She has internationally recognized expertise in breast cancer and molecular pathology, particularly in tumor microenvironment, DNA methylation in phyllodes tumors, and immune evasion in triple-negative breast cancer. Her groundbreaking work includes identifying collagen XII as a driver of metastasis and contributing to the development of a single-cell and spatial atlas of human breast cancers. She leads an international project to develop a single-cell and spatial breast cancer atlas, supported by significant funding from the National Breast Cancer Foundation (>$1.5 million) and the US Department of Defence (over USD $6 million). Professor O'Toole also leads research focused on phyllodes tumors of the breast, a rare and understudied tumor type, providing critical new insights into their epigenetic regulation. With over 150 publications to her name, Professor O'Toole's scholarly output demonstrates a consistent focus on advancing breast cancer diagnostics and treatment. Her work spans molecular pathology, tumor microenvironment analysis, and the development of novel diagnostic approaches. Recent publications highlight her leadership in creating comprehensive breast cancer atlases and refining diagnostic criteria for rare breast tumor types. Her research has significant translational impact, with findings directly influencing clinical practice and health policy. Professor O'Toole's exceptional contributions to cancer research have been recognized with prestigious awards: Eureka Prize 2022 (ANSTO prize for innovative use of technology) as part of NanoM team led by Prof Brian Abbey Roche scientific e-poster prize for DNA methylation in phyllodes tumors (RCPA Updates 2024) Professor O'Toole is deeply committed to mentoring the next generation of pathologists and researchers. She supervises research focused on translational cancer pathology, with particular interests in breast cancer. Her leadership extends to national policy and curriculum development, ensuring pathology remains central to medical and clinical scientific education. She has secured significant research funding, including a National Breast Cancer Foundation grant exceeding $1.5 million and US Department of Defence funding over USD $6 million for her international breast cancer atlas project. Professor O'Toole leads a collaborative research program centered at the Garvan Institute of Medical Research. She serves as the lead pathologist on an international project to develop a single-cell and spatial breast cancer atlas, working with Professor Alexander Swarbrick. She is also part of an international breast pathology expert group focused on phyllodes tumors, led by Professors Puay Hoon Tan and Emad Rakha. Her work involves close collaboration with institutions in Singapore, Sweden, Duke University, and McGill University, reflecting the global impact of her research.

Chi Wangمشاهده پروفایل

استاد

• Cancer Biostatistics
• Bioinformatics
• Survival Analysis
• +۱۰ مورد دیگر

Chi Wang, Ph.D., is Professor of Internal Medicine and Statistics at the University of Kentucky, Associate Director of the Biostatistics & Bioinformatics Shared Resource, and a lead computational scientist within the Markey Cancer Center. With an h-index of 39 and >5,300 citations, he develops cutting-edge survival-analysis and high-dimensional-omics methods that are translated into prostate, breast, lung and neuroblastoma trials. Education: Ph.D. Biostatistics, Johns Hopkins University, 2009 M.S. Statistics, Peking University, 2003 B.S. Mathematics, Peking University, 2001 Research Focus: Wang’s group integrates Bayesian statistics, machine-learning and single-cell sequencing to model tumor evolution, drug resistance and biomarker-driven adaptive trials. Major themes include enzalutamide resistance in prostate cancer, PLK1-mediated immune evasion in lung adenocarcinoma, obesity-adipose drivers of breast cancer, and epigenetic reprogramming of tumor-infiltrating lymphocytes. Recent Article Trends (2023-2025): Fifteen showcased papers reveal a dual trajectory—(1) mechanistic dissection of kinases (PLK1, DDR1, ABL1/2) and metabolic enzymes (FASN, NNMT, HSP47) that orchestrate resistance and metastasis, and (2) probabilistic algorithms for temporal mutation ordering, biomarker evaluation and single-cell deconvolution. Overarching keywords are precision oncology, drug resistance, tumor micro-environment, and computational systems biology. Funding & Awards: He is PI/co-I on 152 grants (32 active) from NCI, ACS, V Foundation, etc., totaling >$30 M direct costs. Highlights include NCI U01 for predictive biomarkers, American Cancer Society award on collagen lysyl hydroxylase metastasis drivers, and NCI R01s targeting NNMT in triple-negative breast cancer and TIL epigenetic reprogramming in NSCLC. Student & Team Mentorship: Wang trains a large multi-disciplinary cohort of Ph.D. students, post-docs and clinical fellows who routinely lead first-author papers and are funded on his grants. His lab sits within the Markey Cancer Center’s Molecular & Cellular Oncology program and the Center for Computational Sciences, fostering daily bench-to-bedside collaboration.

Binhua Zhouمشاهده پروفایل

استاد

• Cancer Metastasis
• Epithelial-Mesenchymal Transition
• Breast Cancer
• +۵ مورد دیگر

Binhua Zhou, Ph.D., holds the Madeline F. James and Edith D. Gardner Chair in Cancer Research at the Markey Cancer Center, University of Kentucky. He serves as Professor in the Department of Molecular and Cellular Biochemistry, Director of the Breast Cancer Research Program, and Program Leader for the Molecular and Cellular Oncology Research Program. His academic qualifications include a Doctor of Medicine from Guangzhou Medical College (1986), a Ph.D. from the University of Texas at Austin (1996), and postdoctoral training at the University of Texas Health Science Center (2001). Dr. Zhou's research focuses on molecular mechanisms of cancer metastasis, particularly epithelial-mesenchymal transition (EMT) regulation by Snail/Slug transcription factors in breast and pancreatic cancers. Key areas include metabolic reprogramming in metastasis, signaling pathway alterations, and therapeutic targeting of NNMT in triple-negative breast cancer. His work employs biochemical, molecular, and cellular approaches to identify targets for metastasis prevention. Analysis of recent publications (2020-2025) reveals dominant themes: EMT-linked metabolic adaptation, ferroptosis suppression, STAT3/SNAIL synergy in metastasis, and myeloid cell regulation in breast cancer. His group consistently explores intersections between transcriptional control, tumor metabolism, and microenvironment remodeling. Awards & Honors Young Investigator Award for Breast Cancer Research (1998) Alexander Wang Memorial Award, 3rd Prize (2000) Career Development Award, Ovarian Cancer Spore Program (1999) Wethington Excellence in Research Award (2009) Award for Cancer Research (2009) Dr. Zhou leads multiple NIH-funded projects as Principal Investigator, including NCI grants targeting NNMT in breast cancer progression and DoD-funded obesity-cancer initiatives. He directs the Breast Cancer Research Program, coordinating interdisciplinary teams investigating metastasis mechanisms and therapeutic innovation.

Chang-il Hwangمشاهده پروفایل

دانشیار

• Pancreatic Cancer
• Epigenetics
• Cancer Therapeutics
• +۵ مورد دیگر

Chang-il Hwang is a tenured Associate Professor in the Department of Microbiology and Molecular Genetics at the University of California, Davis. He leads a research lab focused on understanding the genetic and epigenetic underpinnings of pancreatic cancer progression, with a strong emphasis on therapeutic vulnerabilities and organoid-based modeling. Education: D.V.M., Seoul National University, Seoul, South Korea M.S., Seoul National University, Seoul, South Korea Ph.D., Cornell University Research Interests: Dr. Hwang's lab investigates how genetic and epigenetic alterations contribute to pancreatic cancer progression. A major focus is the development and use of pancreatic organoid models to study the epigenetic landscape of cancer. His team explores how BET inhibitors and other epigenetic therapies can be leveraged to target cancer vulnerabilities, particularly in BRCA-deficient and therapy-resistant tumors. His recent work highlights the role of DNA methylation, enhancer reprogramming, and tumor microenvironment interactions in driving metastasis and therapy resistance. The lab also delves into cancer stem cell biology and the metabolic dependencies of pancreatic tumors. Scientific Awards & Recognition: Excellence in Mentoring Undergraduate Researchers, UC Davis UC Davis Comprehensive Cancer Center Affiliate Scholar Award of Excellence (Daniel Pham) Director’s Fellowship (Suyakarn Archasappawat) UC Davis Cancer Center Travel Award (Daniel Pham) Grants & Funding: Dr. Hwang has secured significant funding, including a UC Cancer Research Coordinating Committee (CRCC) Faculty Seed Grant for 2025–2026 to investigate the epigenetics of the pancreatic tumor microenvironment. His lab also received a CRCC Diversity Supplement to support undergraduate researcher Mitchell Huang. Lab & Team: The Hwang Lab is an active research group with graduate students, postdocs, and undergraduates. Notable members include Suyakarn (Sonia) Archasappawat, who recently completed her PhD, and Daniel Pham, a key contributor to cancer epigenetics research. The lab emphasizes mentorship, diversity, and translational research.

Noam Auslanderمشاهده پروفایل

استادیار

• Machine Learning
• Cancer Genomics
• Tumor Microbiome
• +۴ مورد دیگر

Noam Auslander, Ph.D. is an Assistant Professor in the Molecular and Cellular Oncogenesis Program at The Wistar Institute's Ellen and Ronald Caplan Cancer Center. She joined The Wistar Institute in 2021 after completing postdoctoral training at the National Center of Biotechnology Information (NCBI). Dr. Auslander holds a B.S. in computer science and biology from Tel Aviv University and earned her Ph.D. in computer science from the University of Maryland with a combined fellowship at the National Cancer Institute. Dr. Auslander's research focuses on developing advanced machine and deep learning methods to identify factors that drive cancer development and predict patient prognoses. Her work specifically targets the development of deep learning methods to identify new infectious agents in cancer and biologically interpretable machine learning strategies that improve outcome prediction. Her laboratory has several key research directions: Characterization of the Tumor Microbiome with Machine Learning, Quantification of Gut Microbial Genes and Development of Fecal Biomarkers, New Virus Characterization and Detection of Pathogenic Viral Sequences, and Biologically Informed Classifiers of Cancer Treatment Responses. Her publication record demonstrates a strong trajectory in computational cancer biology, with recent high-impact publications in Nature Communications, Nature Medicine, and other top-tier journals. Her work bridges the gap between complex computational methods and biological insights, with particular emphasis on making machine learning models biologically interpretable for clinical translation. V Foundation Grant for Cancer Research ($600,000) Women Scientists Innovation Award for Cancer Research Dr. Auslander leads a research team including a postdoctoral fellow (Abdurrahman Elbasir), graduate students (Anastasia Lucas, Andrew Patterson, Julia C Malnak), and research staff (McKenna Reale, Bryant Duong). Her lab received significant funding for a project aimed at improving immunotherapy responses in cancer patients by identifying reliable biomarkers that predict patient responses to immunotherapy treatments.

Imran Ahmedمشاهده پروفایل

مدرس ارشد

• Artificial Intelligence
• Machine Learning
• Deep Learning
• +۹ مورد دیگر

Dr. Imran Ahmed serves as a Senior Lecturer in Artificial Intelligence at Anglia Ruskin University's Faculty of Science and Engineering, School of Computing and Information Science. With over 100 research publications exceeding 250 JCR impact factor and an h-index greater than 30, he represents a distinguished academic in computer science and engineering fields. Dr. Ahmed's research spans multiple domains of artificial intelligence, with particular expertise in machine learning, deep learning, computer vision, and data science. His work focuses on medical imaging applications including brain tumor detection, Covid-19 detection, pulmonary nodule classification, and liver lesion detection. He also pioneers research in surveillance systems, IoT-enabled environments, anomaly detection, and AI applications for sustainability in environmental monitoring and precision farming. His recent publications demonstrate a strong trend toward practical AI applications in healthcare, environmental sustainability, and intelligent transportation systems. The research shows increasing emphasis on explainable AI, edge computing implementations, and interdisciplinary approaches that bridge computer science with medical, environmental, and industrial applications. His work consistently addresses real-world challenges with innovative technical solutions. World's top 2% scientists by Stanford University (2021, 2022) Double Gold Medallist Certificate of merit for brain MRI analysis for tumor detection Numerous awards for teaching, research, and administrative excellence Dr. Ahmed supervises research across multiple domains including medical imaging, healthcare informatics, surveillance systems, environmental monitoring, agricultural technology, recommender systems, anomaly detection, cyber security, public health, urban planning, smart cities, augmented reality, and human-computer interaction. His research projects include Human Surveillance and Activity Recognition, Data Analytics during Covid-19, Sustainable Healthcare applications, Deep Learning in Medical Imaging, and Sustainable Environmental Control frameworks. As Principal Investigator, he has led multiple funded projects integrating IoT and AI technologies for practical applications. He is actively involved in organizing technical sessions and workshops for IEEE conferences, particularly focusing on cybersecurity issues of IoT in Ambient Intelligence environments, connected intelligence for IoT applications, and real-time data processing in industrial contexts. His professional memberships include Fellow of the Higher Education Academy, Senior Member of IEEE, Member of ACM Computer Society, and Senior Member of the Institute of Research Engineers and Doctors.

Stanley Riddellمشاهده پروفایل

استاد

• Immunotherapy
• T cell therapy
• CAR T-cell therapy
• +۷ مورد دیگر

Dr. Stanley Riddell is a world-renowned Professor at Fred Hutchinson Cancer Center in the Translational Science and Therapeutics Division. He holds the Burke O'Reilly Family Endowed Chair in Immunotherapy and serves as a Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine. Dr. Riddell is a member of multiple integrated research centers including the Immunotherapy Integrated Research Center (IIRC), Pathogen-Associated Malignancies Integrated Research Center (PAM IRC), and Translational Data Science Integrated Research Center (TDS IRC). Dr. Riddell's educational background includes an MD from the University of Manitoba (1979), followed by a residency in Internal Medicine (1983) and fellowship in Hematology (1985), both also at the University of Manitoba. His clinical expertise centers on hematopoietic stem cell transplantation for leukemias and lymphomas, treating graft-versus-host disease, and developing T cell-based therapies for viral infections and cancers. As a pioneer in immunotherapy research, Dr. Riddell focuses on harnessing T cell biology to develop groundbreaking cancer treatments. His laboratory was instrumental in developing the first human trial of transferred therapeutic T cells to prevent cytomegalovirus infections after stem cell transplantation. His team's breakthroughs include identifying optimal T cell subsets for therapy, developing techniques for isolation and genetic modification of therapeutic T cells, and creating engineered receptors like CARs targeting CD19, BCMA, and ROR1. Dr. Riddell's work has demonstrated remarkable efficacy, with 93% remission rates in acute lymphoblastic leukemia patients treated with CD19 CAR T cells. Analysis of Dr. Riddell's recent publications reveals a strong focus on overcoming challenges in CAR T-cell therapy for solid tumors, particularly breast cancer and lung cancer. His research increasingly addresses metastasis prevention, tumor immune evasion mechanisms, and precision engineering of CAR constructs. Current work emphasizes optimizing T cell subset composition, developing neoantigen-targeted therapies, and creating molecular switches for safer, more effective treatments. Burke O'Reilly Family Endowed Chair in Immunotherapy Dr. Riddell has led numerous clinical trials translating laboratory discoveries into patient treatments. His team developed critical techniques now broadly used in adoptive immunotherapies, including methods for identifying tumor antigens recognized by T cells and rapidly multiplying disease-fighting T cells. Current research focuses on understanding the mechanisms behind both the anti-cancer effects of donor T cells and their role in graft-versus-host disease, dissecting how cancers evade T cell responses, identifying tumor antigens, and elucidating intrinsic T cell properties important for effective therapy. His lab continues to refine approaches to target multiple myeloma and solid tumors while addressing common toxicities of CAR T-cell therapies. The Riddell Lab maintains a robust research program with multiple integrated projects spanning basic T cell biology, receptor engineering, preclinical modeling, and clinical translation. The lab employs various animal models to evaluate new strategies, including human tumor xenografts and orthotopic models. Current emphasis includes developing personalized cancer vaccines targeting tumor-specific neoantigens and creating next-generation CAR constructs with improved safety and efficacy profiles.

• AI Ethics
• Computer Vision
• Large Language Models
• +۵ مورد دیگر

Taha Mansouri is a Lecturer in Artificial Intelligence at the University of Salford's School of Science, Engineering & Environment. He leads the High Performance Computing facilities within the school and chairs the Salford AI Club, an inclusive community focused on AI applications in Higher Education. Mansouri holds dual PhDs - one in Artificial Intelligence and Deep Learning from the University of Salford and another in Information Technology Management from Allameh Tabataba'i University in Iran. His research interests span multiple critical areas in modern AI development, with particular emphasis on ethical considerations in AI systems. Mansouri actively investigates fairness, explainability, and transparency in AI algorithms, with specific focus on computer vision systems and large language models. His work addresses bias in facial emotion detection across age, gender, ethnicity, and cultural backgrounds, highlighting important concerns about equity in automated systems. Mansouri's recent publications demonstrate a strong trend toward practical applications of AI for social good, including detecting mold in social housing, ethical compliance in legal AI systems, and developing AI-resilient assessment tools for education. His research bridges theoretical AI development with real-world implementation challenges across healthcare, education, and industrial applications. Fellowship of the Higher Education Academy Senior Fellowship of the Higher Education Academy Mansouri actively supervises multiple PhD students working on diverse AI applications and leads significant research projects including the £500,000 Innovate UK Smart Grant-funded Expert Legal Intelligence (ELI) project. He serves on prestigious review panels including the EPSRC Peer Review College, the EDI Hub+ Flexible Fund Peer Review College, and the British Council's International Science Partnerships Fund Review College. His grant portfolio includes projects on ethical ASR models (£30,000 collaboration), WATCH-AI benchmarking tools, and inclusive AI emotion recognition systems. As leader of the High Performance Computing facilities, Mansouri supports interdisciplinary research across the university. He also chairs the Salford AI Club, fostering collaboration among individuals from diverse backgrounds interested in AI applications, particularly in Higher Education.

Lene Uhrbomمشاهده پروفایل

استاد

• Neuro-oncology
• Glioblastoma research
• Molecular cancer biology
• +۵ مورد دیگر

Lene Uhrbom is Professor of Molecular Brain Tumor Research at Uppsala University's Department of Immunology, Genetics and Pathology within the Faculty of Medicine. She leads the Neuro-oncology and Neurodegeneration Research Programme and maintains an active research group focused on glioblastoma mechanisms. Her team includes PhD students Veera Jokinen and Ines Neves, Master's student Ellen Rahmqvist, doctoral assistant Xi Lu, and research assistant Rebeca-Noemi Imbria. Her research centers on neuro-oncology with emphasis on glioblastoma stem cells, molecular mechanisms of tumorigenesis, and cell-of-origin studies. She investigates how epigenetic regulation, signaling pathways, and tumor microenvironment interactions drive glioma development and therapeutic resistance. Her work bridges basic molecular biology with translational applications for improved diagnostics and treatments. Analysis of her 15 most recent publications reveals a strong focus on molecular subtyping of glioblastoma, stem cell biology, and therapeutic targeting. Her research consistently explores how cellular lineage, epigenetic regulation, and microenvironmental factors create distinct tumor subgroups with different clinical outcomes. Recent work has expanded into vascular biology, immunotherapy, and advanced imaging techniques for tumor detection. Professor Uhrbom has received significant recognition for her work, with publications in high-impact journals including Nature Communications, Cancer Cell, and Journal of Clinical Investigation. Her research has been featured in multiple news outlets, cited in patents, and referenced in Wikipedia, demonstrating its broad scientific impact. Her laboratory maintains an extensive collection of patient-derived glioblastoma models and employs advanced techniques including single-cell sequencing, epigenetic profiling, and sophisticated mouse models. Current projects focus on developing targeted therapies based on molecular subtyping and improving drug delivery across the blood-brain barrier. She actively collaborates with clinical neuro-oncology teams to translate basic findings into potential therapeutic strategies.

Michael S. Cohenمشاهده پروفایل

دانشیار

• Chemical Biology
• Molecular Design
• NAD+ Regulation
• +۳ مورد دیگر

Michael S. Cohen is an Associate Professor in the Department of Biochemistry and Molecular Biology at Oregon Health & Science University (OHSU) School of Medicine. His research program integrates chemical biology and molecular design to develop novel tools for probing NAD+ regulation and ADP-ribosylation in cellular systems. His educational background includes: B.S. from University of California, Irvine (2000) Ph.D. from University of California, San Francisco (2006) LSRF Postdoctoral Fellowship at Weill Cornell Medical College (2006-2011) Dr. Cohen's laboratory focuses on two interconnected research pillars: (1) elucidating novel roles for NAD+ metabolism in cellular physiology, and (2) deciphering the biological functions of ADP-ribosylation—a post-translational modification catalyzed by PARP enzymes. His team pioneered orthogonal NAD+ analogue-enzyme pairs, selective PARP inhibitors, and real-time NAD+ biosensors that overcome limitations of conventional methods. These chemical tools enable precise manipulation and monitoring of NAD+-dependent processes in living cells. Analysis of his 15 most recent publications (2020-2025) reveals a strategic expansion from fundamental mechanism discovery toward translational applications. Key themes include PARP-mediated immune regulation (e.g., PARP7 in interferon signaling and autoimmunity), cancer immunotherapy enhancement (via PARP11 modulation of regulatory T cells), and neuro-cardiac repair mechanisms. His work bridges chemical biology, immunology, and regenerative medicine through innovative molecular engineering. His scientific recognition includes: Pew Biomedical Scholar (2015) Richard T. Jones New Investigator Award (2016) ICBS Young Chemical Biologist Award (2018) Dr. Cohen mentors graduate students and postdoctoral fellows in chemical biology techniques, with research supported by NIH and foundation grants. His laboratory maintains active collaborations with OHSU clinicians investigating applications in autoimmunity, viral pathogenesis, and cardiac injury models. The Cohen Lab operates within OHSU's collaborative research ecosystem, utilizing core facilities for chemical proteomics and live-cell imaging to translate basic discoveries into therapeutic strategies for NAD+-related pathologies.

Gregory J. Hannonمشاهده پروفایل

استاد

• Small RNA Biology
• RNA Interference
• Cancer Biology
• +۷ مورد دیگر

Gregory J. Hannon is a distinguished Professor at Cold Spring Harbor Laboratory (CSHL) and an Investigator of the Howard Hughes Medical Institute, renowned as one of the world's foremost authorities on small RNA biology and RNA interference. His research has significantly advanced our understanding of gene regulation mechanisms with profound implications for cancer treatment and genome stability. Hannon's educational background includes training that led to his current position as a leading molecular biologist. His research focuses on the biological roles of small RNAs and the mechanisms by which they operate, with particular emphasis on germ cells (which have the most elaborate set of small RNA pathways) and cancer biology (especially breast and pancreatic cancer). His laboratory's groundbreaking work has identified and characterized major biogenesis and effector complexes for small interfering RNAs and microRNAs, including Dicer, RISC, and elements of the Microprocessor. More recently, his team has made significant discoveries regarding piwi-interacting RNAs (piRNAs) and their role in defending the genome from mobile genetic elements. Among his most significant publications are studies on the structure of human Argonaute protein, mechanisms of transposon defense in germ cells, and how breast tissue 'remembers' a first pregnancy through epigenetic changes. His research has consistently appeared in top-tier journals, with several publications recognized by Science as 'Breakthrough of the Year.' Elected to National Academy of Sciences (2012) NIH MERIT Award from National Institute of General Medical Sciences (2013) National Academy of Sciences Award in Molecular Biology (2007) Geoffrey Marshall Mentoring Award from Northeastern Association of Graduate Schools (2011) Howard Hughes Medical Institute Investigator Hannon has mentored 12 postdoctoral fellows and 17 graduate students, with exceptional outcomes including multiple prestigious awards for his trainees. Over 60% of his 200+ publications include graduate student co-authorship. His laboratory has developed innovative technologies including RNAi libraries targeting entire genomes and methods used in Neanderthal genome sequencing. He also serves as director of the Cancer Research UK Cambridge Institute, demonstrating his international leadership in cancer research.

• Proteomics
• Lipidomics
• Metabolomics
• +۳ مورد دیگر

Marcello Manfredi is an Associate Professor at the Department of Translational Medicine, Università degli Studi del Piemonte Orientale 'Amedeo Avogadro'. His research focuses on proteomics, lipidomics, and metabolomics, with applications in infectious diseases (e.g., COVID-19), cancer therapy (e.g., triple-negative breast cancer), and functional food development. He leads projects on universal cancer vaccines (UniCanVax), environmental pollution mitigation (SCENARIOS), and sustainable chemical design (INSIGHT). Collaborations span across Europe and Italy, with expertise in multi-disciplinary approaches to biomedical and environmental challenges. Key research interests include extracellular vesicles, biomarker discovery, and the interplay between diet and chronic diseases. His work aligns with UN Sustainable Development Goals, particularly in health and environmental sustainability. He holds grants from AIRC, the European Commission, and other funding bodies, demonstrating a strong commitment to translational research.

• Genetic Epidemiology
• Mendelian Randomization
• Population-Based Health Surveys
• +۵ مورد دیگر

Ben Michael Brumpton is an Associate Professor in the Department of Community Medicine and Nursing at the Norwegian University of Science and Technology (NTNU), affiliated with the Faculty of Medicine and Health Sciences. His research focuses on genetic epidemiology, particularly leveraging population-based health surveys (e.g., HUNT Study), electronic health records, and omics data to establish causal relationships in public health. Methodologically, he emphasizes Mendelian randomization and genetic epidemiology frameworks. Major Research Projects: HUNT Genotyping HUNT-COVID Questionnaire HUNT Metabolomics HUNT Methylation Research Interests: His work spans DNA methylation analysis, metabolomics, and the integration of omics data into epidemiological studies. He investigates causal links between genetic traits and diseases such as cardiovascular disorders, cancer, and respiratory conditions. Recent studies have explored intergenerational effects of maternal glycemic traits and parental BMI on offspring health outcomes. Publications Overview: His recent work highlights novel genetic loci for chronic low back pain, venous thromboembolism, and celiac disease. He has also contributed to large-scale meta-analyses of atrial fibrillation and breast cancer risk, emphasizing polygenic prediction and Mendelian randomization approaches. Labs/Teams: Primary affiliation with the HUNT Research Center and collaborations within NTNU’s epidemiology and genetics research groups.